Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Imbruvica is a prescription kinase inhibitor containing ibrutinib. It is indicated for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including disease with 17p deletion, and Waldenstr?m macroglobulinemia. It also treats chronic graft-versus-host disease after failure of one or more systemic therapies in adults and children age 1 and older.
read more about imbruvica ...Ibrutinib forms a covalent bond with a cysteine residue in the active site of Bruton tyrosine kinase. This inhibits BTK signaling, which affects survival, proliferation, adhesion, and migration of susceptible malignant B cells.
Imbruvica is used in adults with CLL or SLL, CLL or SLL with 17p deletion, and Waldenstr?m macroglobulinemia. It is also used for chronic graft-versus-host disease after failure of at least one line of systemic therapy in adults and pediatric patients age 1 and older.
Adults with CLL, SLL, or Waldenstr?m macroglobulinemia receive 420 mg by mouth once daily until disease progression or unacceptable toxicity. Patients age 12 and older with chronic graft-versus-host disease receive 420 mg once daily. Patients age 1 to younger than 12 receive 240 mg per square meter once daily, up to 420 mg.
Serious concerns include major bleeding, severe infections, cardiac arrhythmias, heart failure, sudden death, high blood pressure, low blood-cell counts, second primary cancers, liver toxicity, tumor lysis syndrome, and fetal harm. Strong CYP3A inhibitors can raise ibrutinib exposure and require avoidance, interruption, or dose adjustment.
Current labeling includes CLL, SLL, Waldenstr?m macroglobulinemia, and chronic graft-versus-host disease after prior systemic therapy.
The recommended dose is 420 mg once daily.
Yes. Major and fatal bleeding events have occurred during treatment.
Yes. Cardiac arrhythmias, heart failure, and sudden death have been reported.
DailyMed - IMBRUVICA - ibrutinib capsule, tablet, and oral suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44. Date Accessed October 2, 2026.
FDA Approves Treatment for Chronic Graft Versus Host Disease. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-graft-versus-host-disease. Date Accessed October 2, 2026.
Ibrutinib - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a614007.html. Date Accessed October 2, 2026.
Ibrutinib - National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib. Date Accessed October 2, 2026.
Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab in Patients With Chronic Lymphocytic Leukemia. https://pubmed.ncbi.nlm.nih.gov/30530801/. Date Accessed October 2, 2026.